Edgar Filing: ZAMBROWICZ BRIAN P - Form 4

	VICZ BRIAN P										
Form 4 February 04,	2013										
FORM	Л								OMB A	PPROVAL	
UNITED STATES SECON				RITIES AND EXCHANGE COMMISSION shington, D.C. 20549				Number:	3235-0287		
if no long subject to Section 1 Form 4 o Form 5 obligatio may cont See Instru 1(b).	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					January 31 Expires: 2005 Estimated average burden hours per response 0.5					
(Print or Type I	Responses)										
1. Name and Address of Reporting Person * 2. Iss ZAMBROWICZ BRIAN P Symbol LEXX			Symbol LEXICO	uer Name and Ticker or Trading d CON PHARMACEUTICALS, DE [LXRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Mor				ate of Earliest Transaction nth/Day/Year) 31/2013 Amendment, Date Original I(Month/Day/Year)				 Director 10% Owner _X Officer (give title Other (specify below) EVP, Chief Scientific Officer 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	(Street) 4. If Ame Filed(Mor										
THE WOOI	DLANDS, TX 7	7381						Person		porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, i any (Month/Day/Year)		on Date, if	Code (Instr. 3, 4 and 5) (Instr. 8) (A)				Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Stock	01/31/2013			М	42,100	А	<u>(1)</u>	216,580	D		
Common Stock	01/31/2013			F <u>(2)</u>	13,499	D	\$ 2.11	203,081	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ZAMBROWICZ BRIAN P - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted Stock Units (Phantom Stock)	<u>(1)</u>	01/31/2013		М	42,100	(3)	(3)	Common Stock	42,100	

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
ZAMBROWICZ BRIAN P 8800 TECHNOLOGY FOREST PLA THE WOODLANDS, TX 77381	ACE		EVP, Chief Scientific Officer					
Signatures								
/s/ Brian P. Zambrowicz, Ph.D.	02/01/2013							

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of common stock.
- (2) Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product

(3) discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.